Skip to content
PeptideFactSheets
Not FDA approvedEarly human evidence

Gut-microbiome-derived metabolite fact sheet

Urolithin A

Also known as UA, pomegranate-derived postbiotic

Mitochondrial healthMuscle and performanceHealthy agingImmune and infection

Urolithin A is produced from dietary ellagitannins by some gut microbiomes. Sponsored trials report mitochondrial biomarker and selected muscle signals, while key primary outcomes have not always improved.

Quick answer

Urolithin A has early human evidence for target engagement and selected muscle-endurance outcomes, but it is not an FDA-approved drug for aging, muscle loss, mitochondrial disease, or immune decline. Trials have been small and commonly industry sponsored.

Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.

What is Urolithin A?

Urolithin A is a metabolite made when certain gut bacteria process ellagitannins found in foods such as pomegranates and walnuts.

It is studied as a trigger of mitophagy, the cellular process that removes damaged mitochondria.

Why are people interested in it?

Mitochondrial quality control is relevant to aging, muscle function, and immune-cell biology.

Human studies provide a stronger translational base than many frontier compounds, but sponsor involvement, modest samples, and mixed endpoints call for independent replication.

Current regulatory status

Not FDA approved

Urolithin A is not an FDA-approved drug for any aging, muscle, mitochondrial, or immune indication. Supplement availability is not evidence of FDA-reviewed effectiveness.

What is it approved for?

No approved use is documented by the records summarized here. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.

Approval and research context

No FDA-approved drug use

Urolithin A has human supplement-style trials and biomarker outcomes, but no FDA-approved drug indication for mitochondrial health, muscle function, or aging.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What is it being studied for?

Mitophagy and mitochondrial biomarkers
Muscle endurance and physical performance
Age-related immune changes
Healthy-aging biology

Evidence snapshot

Early human evidence

Randomized human studies show biochemical target engagement and some secondary muscle or immune signals. In one older-adult trial, the primary walking-distance and ATP-production outcomes were not significantly better than placebo.

Potential benefits being researched

  • A controlled older-adult trial reported better muscle endurance and biomarker changes but did not improve its primary walking-distance or ATP-production outcomes over placebo.
  • Other sponsored trials report muscle-performance or immune-cell signals that need confirmation in larger independent studies.

A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.

Known or possible risks

  • Short trials generally reported similar adverse-event rates to placebo, but sample sizes were too small to define uncommon harms.
  • Several pivotal human studies involved the ingredient developer or sponsor, a conflict that does not invalidate results but increases the value of independent replication.
  • Commercial supplement quality may not match trial material.

What we still do not know

  • Whether effects persist or translate into less disability or disease
  • Whether independent trials reproduce sponsor-linked findings
  • Long-term safety across diverse populations
  • Which people, if any, have a clinically meaningful response

Plain-English takeaway

Urolithin A has promising early human work, but mixed endpoints and a sponsor-heavy evidence base make it a research candidate—not a proven anti-aging therapy.

Research and reference links

Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.

  1. 1
    pubmedRandomized urolithin A trial in older adults

    Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.

  2. 2
    pubmedRandomized trial in middle-aged adults

    Industry-sponsored study of muscle performance and mitochondrial biomarkers.

  3. 3
    pubmedFirst-in-human urolithin A study

    Early study establishing bioavailability, short-term tolerability, and biomarker effects.

  4. 4
    fdaFDA: what ‘FDA approved’ does and does not mean

    FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.